CG Oncology, Inc. (CGON)
(Delayed Data from NSDQ)
$35.41 USD
+0.95 (2.76%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $35.46 +0.05 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
CG Oncology, Inc. (CGON) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$67.67 | $86.00 | $50.00 | 96.37% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for CG Oncology, Inc. comes to $67.67. The forecasts range from a low of $50.00 to a high of $86.00. The average price target represents an increase of 96.37% from the last closing price of $34.46.
Analyst Price Targets (6 )
Broker Rating
CG Oncology, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 5 | 5 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/28/2024 | H.C. Wainwright & Co. | Andres Y Maldonado | Strong Buy | Strong Buy |
5/13/2024 | Goldman Sachs | Christopher Johnson | Hold | Strong Buy |
5/2/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
2/20/2024 | LifeSci Capital | Sam Slutsky | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $67.67 |
LT Growth Rate | 57.40% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.42 |